Ignite Creation Date:
2025-12-24 @ 9:07 PM
Ignite Modification Date:
2026-04-03 @ 3:59 AM
Study NCT ID:
NCT02536404
Status:
COMPLETED
Last Update Posted:
2021-11-26
First Post:
2015-08-24
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003093', 'term': 'Colitis, Ulcerative'}], 'ancestors': [{'id': 'D003092', 'term': 'Colitis'}, {'id': 'D005759', 'term': 'Gastroenteritis'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D015212', 'term': 'Inflammatory Bowel Diseases'}, {'id': 'D003108', 'term': 'Colonic Diseases'}, {'id': 'D007410', 'term': 'Intestinal Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000656249', 'term': 'etrasimod'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'ct.gov@arenapharm.com', 'phone': '+1 855-218-9153', 'title': 'Arena CT.gov Administrator', 'organization': 'Arena Pharmaceuticals, Inc.'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'timeFrame': 'Up to Week 48 (up to 30 days following discontinuation of the study drug)', 'description': 'A TEAE was defined as any adverse event (AE) that occurred after the first dose of study drug in the APD334-005 (NCT02536404) study, including any AE that started in Study APD334-003 (NCT02447302) and was ongoing, worsened, or ended in Study APD334-005. A SAE was any untoward medical occurrence that at any dose resulted in the following outcomes: death, was life-threatening, required/prolonged hospitalization, disability/incapacity, congenital anomaly/birth defect, and important medical events.', 'eventGroups': [{'id': 'EG000', 'title': 'Etrasimod 2 mg', 'description': 'Participants received etrasimod 2 milligrams (mg) tablet by mouth, once daily for 34 weeks in fasted state.', 'otherNumAtRisk': 112, 'deathsNumAtRisk': 112, 'otherNumAffected': 66, 'seriousNumAtRisk': 112, 'deathsNumAffected': 0, 'seriousNumAffected': 7}, {'id': 'EG001', 'title': 'Placebo', 'description': 'Participants received matching placebo tablet by mouth, once daily for 34 weeks in fasted state.', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 5, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Gamma-glutamyltransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 10}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Aspartate aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Faecal calprotectin increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Hepatic enzyme increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 10}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Carpal tunnel syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Vitreous', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Colitis ulcerative', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 16}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Dental caries', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Gastritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Glossodynia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Large intestine polyp', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Premenstrual headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 1}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Rash', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Musculoskeletal chest pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Hyperparathyroidism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 1}], 'organSystem': 'Endocrine disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Gastroenteritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Bronchitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Chronic sinusitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Herpes zoster', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Influenza', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}, {'term': 'Tooth infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.1'}], 'seriousEvents': [{'term': 'Iron deficiency anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDra 20.1'}, {'term': 'Atrial fibrillation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDra 20.1'}, {'term': 'Colitis ulcerative', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDra 20.1'}, {'term': 'Large intestine perforation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDra 20.1'}, {'term': 'Pancreatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDra 20.1'}, {'term': 'Proctitis ulcerative', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDra 20.1'}, {'term': 'Gastroenteritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDra 20.1'}, {'term': 'Fine motor skill dysfunction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDra 20.1'}, {'term': 'Transient ischaemic attack', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDra 20.1'}, {'term': 'Cystitis haemorrhagic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 112, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 6, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDra 20.1'}], 'frequencyThreshold': '2'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '112', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Etrasimod 2 mg', 'description': 'Participants received etrasimod 2 mg tablet by mouth, once daily for 34 weeks in fasted state.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Participants received matching placebo tablet by mouth, once daily for 34 weeks in fasted state.'}], 'classes': [{'title': 'TEAEs', 'categories': [{'measurements': [{'value': '67', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}]}, {'title': 'Treatment-emergent SAEs', 'categories': [{'measurements': [{'value': '7', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to Week 48 (up to 30 days following discontinuation of the study drug)', 'description': 'A TEAE was defined as any adverse event (AE) that occurred after the first dose of study drug in the APD334-005 (NCT02536404) study, including any AE that started in Study APD334-003 (NCT02447302) and was ongoing, worsened, or ended in Study APD334-005. A SAE was any untoward medical occurrence that at any dose resulted in the following outcomes: death, was life-threatening, required/prolonged hospitalization, disability/incapacity, congenital anomaly/birth defect, and important medical events.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety Population: All randomized participants who received study medication in the extension study APD334-005'}, {'type': 'SECONDARY', 'title': 'Proportion of Participants Who Achieved Clinical Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '84', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Etrasimod 2 mg', 'description': 'Participants received etrasimod 2 mg tablet by mouth, once daily for 34 weeks in fasted state.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Participants received matching placebo tablet by mouth, once daily for 34 weeks in fasted state.'}], 'classes': [{'categories': [{'measurements': [{'value': '78.6', 'groupId': 'OG000', 'lowerLimit': '69.9', 'upperLimit': '85.7'}, {'value': '75.0', 'groupId': 'OG001', 'lowerLimit': '24.9', 'upperLimit': '98.7'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 46 (extension study APD334-005)', 'description': 'A participant was considered to have achieved clinical response if he/she met the criteria of clinical remission or met criteria of clinical response. Clinical remission was defined as individual subscores of the 3-component Mayo Clinic score as follows: (1) an endoscopy score (using flexible proctosigmoidoscopy) of 0 or 1, (2) a rectal bleeding score of 0, and (3) a stool frequency score of 0 or 1 with a decrease of ≥ 1 point at Week 46 compared to APD334-003 baseline. Clinical response was defined as a decrease in 3-component Mayo Clinic score of ≥ 2 points and at least 30% with either a decrease of rectal bleeding of ≥ 1 or rectal bleeding score of 0 or 1 at Week 46 compared with baseline of study APD334-003. A score of 0 = normal and 1 = mild disease.', 'unitOfMeasure': 'Percentage of participants', 'dispersionType': '90% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Completers Population Evaluable Cohort: All participants who received at least 1 dose of etrasimod or placebo and completed the extension study APD334-005'}, {'type': 'SECONDARY', 'title': 'Proportion of Participants Who Achieved Clinical Response at Week 12 in APD334-003 and Maintained Clinical Response at Week 46 in APD334-005', 'denoms': [{'units': 'Participants', 'counts': [{'value': '84', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Etrasimod 2 mg', 'description': 'Participants received etrasimod 2 mg tablet by mouth, once daily for 34 weeks in fasted state.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Participants received matching placebo tablet by mouth, once daily for 34 weeks in fasted state.'}], 'classes': [{'categories': [{'measurements': [{'value': '39.3', 'groupId': 'OG000', 'lowerLimit': '30.3', 'upperLimit': '48.8'}, {'value': '50.0', 'groupId': 'OG001', 'lowerLimit': '9.8', 'upperLimit': '90.2'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 12 (core study APD334-003) and Week 46 (extension study APD334-005)', 'description': 'A participant was considered to have achieved clinical response if he/she met the criteria of clinical remission or met criteria of clinical response. Clinical remission was defined as individual subscores of the 3-component Mayo Clinic score as follows: (1) an endoscopy score (using flexible proctosigmoidoscopy) of 0 or 1, (2) a rectal bleeding score of 0, and (3) a stool frequency score of 0 or 1 with a decrease of ≥ 1 point at Week 46 compared to APD334-003 baseline. Clinical response was defined as a decrease in 3-component Mayo Clinic score of ≥ 2 points and at least 30% with either a decrease of rectal bleeding of ≥ 1 or rectal bleeding score of 0 or 1 at Week 46 compared with baseline of study APD334-003. A score of 0 = normal and 1 = mild disease.', 'unitOfMeasure': 'Percentage of participants', 'dispersionType': '90% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Completers Population Evaluable Cohort'}, {'type': 'SECONDARY', 'title': 'Proportion of Participants Who Achieved Clinical Remission', 'denoms': [{'units': 'Participants', 'counts': [{'value': '84', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Etrasimod 2 mg', 'description': 'Participants received etrasimod 2 mg tablet by mouth, once daily for 34 weeks in fasted state.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Participants received matching placebo tablet by mouth, once daily for 34 weeks in fasted state.'}], 'classes': [{'categories': [{'measurements': [{'value': '39.3', 'groupId': 'OG000', 'lowerLimit': '30.3', 'upperLimit': '48.8'}, {'value': '25.0', 'groupId': 'OG001', 'lowerLimit': '1.3', 'upperLimit': '75.1'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 46 (extension study APD334-005)', 'description': 'A participant was considered to have achieved clinical remission if he/she had: (1) an endoscopy score (using flexible proctosigmoidoscopy) of 0 or 1, (2) a rectal bleeding score of 0, and (3) a stool frequency score of 0 or 1 with a decrease of ≥ 1 point at Week 46 compared with baseline of study APD334-003. A score of 0 = normal and 1 = mild disease.', 'unitOfMeasure': 'Percentage of participants', 'dispersionType': '90% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Completers Population Evaluable Cohort'}, {'type': 'SECONDARY', 'title': 'Proportion of Participants Who Achieved Clinical Remission at Week 12 in APD334-003 and Also Maintained Clinical Remission at Week 46 in APD334-005', 'denoms': [{'units': 'Participants', 'counts': [{'value': '84', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Etrasimod 2 mg', 'description': 'Participants received etrasimod 2 mg tablet by mouth, once daily for 34 weeks in fasted state.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'Participants received matching placebo tablet by mouth, once daily for 34 weeks in fasted state.'}], 'classes': [{'categories': [{'measurements': [{'value': '14.3', 'groupId': 'OG000', 'lowerLimit': '8.5', 'upperLimit': '22.1'}, {'value': '0', 'groupId': 'OG001', 'lowerLimit': '0.0', 'upperLimit': '52.7'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 12 (core study APD334-003) and Week 46 (extension study APD334-005)', 'description': 'A participant was considered to have achieved clinical remission if he/she had: (1) an endoscopy score (using flexible proctosigmoidoscopy) of 0 or 1, (2) a rectal bleeding score of 0, and (3) a stool frequency score of 0 or 1 with a decrease of ≥ 1 point at Week 46 compared with baseline of study APD334-003. A score of 0 = normal and 1 = mild disease.', 'unitOfMeasure': 'Percentage of participants', 'dispersionType': '90% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Completers Population Evaluable Cohort'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Etrasimod 2 mg', 'description': 'Participants received etrasimod 2 milligrams (mg) tablet by mouth, once daily for 34 weeks in fasted state.'}, {'id': 'FG001', 'title': 'Placebo', 'description': 'Participants received matching placebo tablet by mouth, once daily for 34 weeks in fasted state.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '112'}, {'groupId': 'FG001', 'numSubjects': '6'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '92'}, {'groupId': 'FG001', 'numSubjects': '5'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '20'}, {'groupId': 'FG001', 'numSubjects': '1'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '5'}, {'groupId': 'FG001', 'numSubjects': '0'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'Physician Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '10'}, {'groupId': 'FG001', 'numSubjects': '0'}]}, {'type': 'Sponsor decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '112', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '118', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Etrasimod 2 mg', 'description': 'Participants received etrasimod 2 milligrams (mg) tablet by mouth, once daily for 34 weeks in fasted state.'}, {'id': 'BG001', 'title': 'Placebo', 'description': 'Participants received matching placebo tablet by mouth, once daily for 34 weeks in fasted state.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '43.7', 'spread': '13.25', 'groupId': 'BG000'}, {'value': '50.2', 'spread': '13.93', 'groupId': 'BG001'}, {'value': '44.0', 'spread': '13.30', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '44', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '47', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '68', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '71', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '108', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '114', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}, {'title': 'Black or African American', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}, {'title': 'White', 'measurements': [{'value': '104', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '110', 'groupId': 'BG002'}]}, {'title': 'More than one race', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'Baseline data are reported for members of the Safety Population, comprised of all participants who received study medication in the extension study APD334-005 (NCT02536404).'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2017-04-03', 'size': 5215740, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2021-10-29T14:48', 'hasProtocol': True}, {'date': '2018-11-27', 'size': 1063803, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2021-10-29T12:50', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 118}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2016-01-25', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2021-11', 'dispFirstSubmitDate': '2019-10-31', 'completionDateStruct': {'date': '2018-11-01', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2021-11-24', 'studyFirstSubmitDate': '2015-08-24', 'dispFirstSubmitQcDate': '2019-10-31', 'resultsFirstSubmitDate': '2021-10-29', 'studyFirstSubmitQcDate': '2015-08-27', 'dispFirstPostDateStruct': {'date': '2019-11-06', 'type': 'ACTUAL'}, 'lastUpdatePostDateStruct': {'date': '2021-11-26', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2021-11-24', 'studyFirstPostDateStruct': {'date': '2015-08-31', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2021-11-26', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2018-11-01', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs)', 'timeFrame': 'Up to Week 48 (up to 30 days following discontinuation of the study drug)', 'description': 'A TEAE was defined as any adverse event (AE) that occurred after the first dose of study drug in the APD334-005 (NCT02536404) study, including any AE that started in Study APD334-003 (NCT02447302) and was ongoing, worsened, or ended in Study APD334-005. A SAE was any untoward medical occurrence that at any dose resulted in the following outcomes: death, was life-threatening, required/prolonged hospitalization, disability/incapacity, congenital anomaly/birth defect, and important medical events.'}], 'secondaryOutcomes': [{'measure': 'Proportion of Participants Who Achieved Clinical Response', 'timeFrame': 'Week 46 (extension study APD334-005)', 'description': 'A participant was considered to have achieved clinical response if he/she met the criteria of clinical remission or met criteria of clinical response. Clinical remission was defined as individual subscores of the 3-component Mayo Clinic score as follows: (1) an endoscopy score (using flexible proctosigmoidoscopy) of 0 or 1, (2) a rectal bleeding score of 0, and (3) a stool frequency score of 0 or 1 with a decrease of ≥ 1 point at Week 46 compared to APD334-003 baseline. Clinical response was defined as a decrease in 3-component Mayo Clinic score of ≥ 2 points and at least 30% with either a decrease of rectal bleeding of ≥ 1 or rectal bleeding score of 0 or 1 at Week 46 compared with baseline of study APD334-003. A score of 0 = normal and 1 = mild disease.'}, {'measure': 'Proportion of Participants Who Achieved Clinical Response at Week 12 in APD334-003 and Maintained Clinical Response at Week 46 in APD334-005', 'timeFrame': 'Week 12 (core study APD334-003) and Week 46 (extension study APD334-005)', 'description': 'A participant was considered to have achieved clinical response if he/she met the criteria of clinical remission or met criteria of clinical response. Clinical remission was defined as individual subscores of the 3-component Mayo Clinic score as follows: (1) an endoscopy score (using flexible proctosigmoidoscopy) of 0 or 1, (2) a rectal bleeding score of 0, and (3) a stool frequency score of 0 or 1 with a decrease of ≥ 1 point at Week 46 compared to APD334-003 baseline. Clinical response was defined as a decrease in 3-component Mayo Clinic score of ≥ 2 points and at least 30% with either a decrease of rectal bleeding of ≥ 1 or rectal bleeding score of 0 or 1 at Week 46 compared with baseline of study APD334-003. A score of 0 = normal and 1 = mild disease.'}, {'measure': 'Proportion of Participants Who Achieved Clinical Remission', 'timeFrame': 'Week 46 (extension study APD334-005)', 'description': 'A participant was considered to have achieved clinical remission if he/she had: (1) an endoscopy score (using flexible proctosigmoidoscopy) of 0 or 1, (2) a rectal bleeding score of 0, and (3) a stool frequency score of 0 or 1 with a decrease of ≥ 1 point at Week 46 compared with baseline of study APD334-003. A score of 0 = normal and 1 = mild disease.'}, {'measure': 'Proportion of Participants Who Achieved Clinical Remission at Week 12 in APD334-003 and Also Maintained Clinical Remission at Week 46 in APD334-005', 'timeFrame': 'Week 12 (core study APD334-003) and Week 46 (extension study APD334-005)', 'description': 'A participant was considered to have achieved clinical remission if he/she had: (1) an endoscopy score (using flexible proctosigmoidoscopy) of 0 or 1, (2) a rectal bleeding score of 0, and (3) a stool frequency score of 0 or 1 with a decrease of ≥ 1 point at Week 46 compared with baseline of study APD334-003. A score of 0 = normal and 1 = mild disease.'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'conditions': ['Ulcerative Colitis']}, 'referencesModule': {'references': [{'pmid': '39778975', 'type': 'DERIVED', 'citation': 'Vermeire S, Rubin DT, Peyrin-Biroulet L, Dubinsky MC, Regueiro M, Irving PM, Goetsch M, Lazin K, Gu G, Wu J, Modesto I, McDonnell A, Guo X, Green J, Dalam AB, Yarur AJ. Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis. BMJ Open Gastroenterol. 2025 Jan 8;12(1):e001516. doi: 10.1136/bmjgast-2024-001516.'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to determine whether etrasimod (APD334) is a safe and effective treatment for ulcerative colitis after 52 weeks of treatment.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Participants who completed the APD334-003 (NCT02447302) study\n\nExclusion Criteria:\n\n* Participants who did not complete the APD334-003 study'}, 'identificationModule': {'nctId': 'NCT02536404', 'briefTitle': 'Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis', 'organization': {'class': 'INDUSTRY', 'fullName': 'Arena Pharmaceuticals'}, 'officialTitle': 'Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis', 'orgStudyIdInfo': {'id': 'APD334-005'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Etrasimod 2 mg', 'interventionNames': ['Drug: Etrasimod']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Placebo', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'name': 'Etrasimod', 'type': 'DRUG', 'otherNames': ['APD334'], 'armGroupLabels': ['Etrasimod 2 mg']}, {'name': 'Placebo', 'type': 'DRUG', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '35294', 'city': 'Birmingham', 'state': 'Alabama', 'country': 'United States', 'facility': 'Arena 1119', 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}}, {'zip': '36305', 'city': 'Dothan', 'state': 'Alabama', 'country': 'United States', 'facility': 'Arena 1133', 'geoPoint': {'lat': 31.22323, 'lon': -85.39049}}, {'zip': '91360', 'city': 'Thousand Oaks', 'state': 'California', 'country': 'United States', 'facility': 'Arena 1143', 'geoPoint': {'lat': 34.17056, 'lon': -118.83759}}, {'zip': '33021', 'city': 'Hollywood', 'state': 'Florida', 'country': 'United States', 'facility': 'Arena 1107', 'geoPoint': {'lat': 26.0112, 'lon': -80.14949}}, {'zip': '33134', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Arena 1138', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '34102', 'city': 'Naples', 'state': 'Florida', 'country': 'United States', 'facility': 'Arena 1123', 'geoPoint': {'lat': 26.14234, 'lon': -81.79596}}, {'zip': '32825', 'city': 'Orlando', 'state': 'Florida', 'country': 'United States', 'facility': 'Arena 1141', 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'zip': '32127', 'city': 'Port Orange', 'state': 'Florida', 'country': 'United States', 'facility': 'Arena 1106', 'geoPoint': {'lat': 29.13832, 'lon': -80.99561}}, {'zip': '33172', 'city': 'Sweetwater', 'state': 'Florida', 'country': 'United States', 'facility': 'Arena 1137', 'geoPoint': {'lat': 25.76343, 'lon': -80.37311}}, {'zip': '60611', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'Arena 1131', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '60169', 'city': 'Hoffman Estates', 'state': 'Illinois', 'country': 'United States', 'facility': 'Arena 1139', 'geoPoint': {'lat': 42.04281, 'lon': -88.0798}}, {'zip': '61801', 'city': 'Urbana', 'state': 'Illinois', 'country': 'United States', 'facility': 'Arena 1127', 'geoPoint': {'lat': 40.11059, 'lon': -88.20727}}, {'zip': '20815', 'city': 'Chevy Chase', 'state': 'Maryland', 'country': 'United States', 'facility': 'Arena 1113', 'geoPoint': {'lat': 39.00287, 'lon': -77.07115}}, {'zip': '49686', 'city': 'Traverse City', 'state': 'Michigan', 'country': 'United States', 'facility': 'Arena 1142', 'geoPoint': {'lat': 44.76306, 'lon': -85.62063}}, {'zip': '48098', 'city': 'Troy', 'state': 'Michigan', 'country': 'United States', 'facility': 'Arena 1111', 'geoPoint': {'lat': 42.60559, 'lon': -83.14993}}, {'zip': '11021', 'city': 'Great Neck', 'state': 'New York', 'country': 'United States', 'facility': 'Arena 1109', 'geoPoint': {'lat': 40.80066, 'lon': -73.72846}}, {'zip': '14642', 'city': 'Rochester', 'state': 'New York', 'country': 'United States', 'facility': 'Arena 1114', 'geoPoint': {'lat': 43.15478, 'lon': -77.61556}}, {'zip': '27612', 'city': 'Raleigh', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Arena 1118', 'geoPoint': {'lat': 35.7721, 'lon': -78.63861}}, {'zip': '45267', 'city': 'Cincinnati', 'state': 'Ohio', 'country': 'United States', 'facility': 'Arena 1112', 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'zip': '15219', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Arena 1117', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'zip': '38138', 'city': 'Germantown', 'state': 'Tennessee', 'country': 'United States', 'facility': 'Arena 1105', 'geoPoint': {'lat': 35.08676, 'lon': -89.81009}}, {'zip': '37076', 'city': 'Hermitage', 'state': 'Tennessee', 'country': 'United States', 'facility': 'Arena 1102', 'geoPoint': {'lat': 36.19617, 'lon': -86.6225}}, {'zip': '75115', 'city': 'DeSoto', 'state': 'Texas', 'country': 'United States', 'facility': 'Arena 1136', 'geoPoint': {'lat': 32.58986, 'lon': -96.85695}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Arena 1121', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '76508', 'city': 'Temple', 'state': 'Texas', 'country': 'United States', 'facility': 'Arena 1116', 'geoPoint': {'lat': 31.09823, 'lon': -97.34278}}, {'zip': '84405', 'city': 'Ogden', 'state': 'Utah', 'country': 'United States', 'facility': 'Arena 1103', 'geoPoint': {'lat': 41.223, 'lon': -111.97383}}, {'zip': '23298', 'city': 'Richmond', 'state': 'Virginia', 'country': 'United States', 'facility': 'Arena 1130', 'geoPoint': {'lat': 37.55376, 'lon': -77.46026}}, {'zip': '24014', 'city': 'Roanoke', 'state': 'Virginia', 'country': 'United States', 'facility': 'Arena 1128', 'geoPoint': {'lat': 37.27097, 'lon': -79.94143}}, {'zip': '98101', 'city': 'Seattle', 'state': 'Washington', 'country': 'United States', 'facility': 'Arena 1115', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}, {'zip': '98195', 'city': 'Seattle', 'state': 'Washington', 'country': 'United States', 'facility': 'Arena 1101', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}, {'zip': '53226', 'city': 'Wauwatosa', 'state': 'Wisconsin', 'country': 'United States', 'facility': 'Arena 1108', 'geoPoint': {'lat': 43.04946, 'lon': -88.00759}}, {'zip': '2747', 'city': 'Kingswood', 'country': 'Australia', 'facility': 'Arena 1604', 'geoPoint': {'lat': -33.75614, 'lon': 150.72346}}, {'zip': '2031', 'city': 'Randwick', 'country': 'Australia', 'facility': 'Arena 1605', 'geoPoint': {'lat': -33.91439, 'lon': 151.24895}}, {'zip': '6008', 'city': 'Subiaco', 'country': 'Australia', 'facility': 'Arena 1607', 'geoPoint': {'lat': -31.9485, 'lon': 115.8268}}, {'zip': '1090', 'city': 'Vienna', 'country': 'Austria', 'facility': 'Arena 1490', 'geoPoint': {'lat': 48.20849, 'lon': 16.37208}}, {'zip': '2650', 'city': 'Edegem', 'country': 'Belgium', 'facility': 'Arena 1472', 'geoPoint': {'lat': 51.15662, 'lon': 4.44504}}, {'zip': '8500', 'city': 'Kortrijk', 'country': 'Belgium', 'facility': 'Arena 1464', 'geoPoint': {'lat': 50.82803, 'lon': 3.26487}}, {'zip': '3000', 'city': 'Leuven', 'country': 'Belgium', 'facility': 'Arena 1473', 'geoPoint': {'lat': 50.87959, 'lon': 4.70093}}, {'zip': '1407', 'city': 'Rousse', 'country': 'Bulgaria', 'facility': 'Arena 1421', 'geoPoint': {'lat': 43.84872, 'lon': 25.9534}}, {'zip': '1407', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'Arena 1417', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '1527', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'Arena 1410', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '1784', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'Arena 1409', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '1797', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'Arena 1407', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '9010', 'city': 'Varna', 'country': 'Bulgaria', 'facility': 'Arena 1425', 'geoPoint': {'lat': 43.21912, 'lon': 27.91024}}, {'zip': 'R3A 1R9', 'city': 'Winnipeg', 'state': 'Manitoba', 'country': 'Canada', 'facility': 'Arena 1202', 'geoPoint': {'lat': 49.8844, 'lon': -97.14704}}, {'zip': 'B4V 3N2', 'city': 'Bridgewater', 'state': 'Nova Scotia', 'country': 'Canada', 'facility': 'Arena 1210', 'geoPoint': {'lat': 44.37856, 'lon': -64.51882}}, {'zip': 'P3E 1H5', 'city': 'Greater Sudbury', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Arena 1208', 'geoPoint': {'lat': 46.49, 'lon': -80.99001}}, {'zip': 'P3E 6C3', 'city': 'Greater Sudbury', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Arena 1209', 'geoPoint': {'lat': 46.49, 'lon': -80.99001}}, {'zip': 'N6A 4G5', 'city': 'London', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Arena 1206', 'geoPoint': {'lat': 42.98339, 'lon': -81.23304}}, {'zip': 'M5G 1X5', 'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Arena 1204', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'zip': '140 59', 'city': 'Prague', 'country': 'Czechia', 'facility': 'Arena 1455', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '80054', 'city': 'Amiens', 'country': 'France', 'facility': 'Arena 1443', 'geoPoint': {'lat': 49.9, 'lon': 2.3}}, {'zip': '92110', 'city': 'Clichy', 'country': 'France', 'facility': 'Arena 1418', 'geoPoint': {'lat': 48.90018, 'lon': 2.30952}}, {'zip': '59037', 'city': 'Lille', 'country': 'France', 'facility': 'Arena 1437', 'geoPoint': {'lat': 50.63391, 'lon': 3.05512}}, {'zip': '75010', 'city': 'Paris', 'country': 'France', 'facility': 'Arena 1476', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '693110', 'city': 'Pierre-Bénite', 'country': 'France', 'facility': 'Arena 1480', 'geoPoint': {'lat': 45.70359, 'lon': 4.82424}}, {'zip': '42055', 'city': 'Saint-Etienne', 'country': 'France', 'facility': 'Arena 1423', 'geoPoint': {'lat': 45.43389, 'lon': 4.39}}, {'zip': '54511', 'city': 'Vandœuvre-lès-Nancy', 'country': 'France', 'facility': 'Arena 1457', 'geoPoint': {'lat': 48.66115, 'lon': 6.17114}}, {'zip': '20249', 'city': 'Hamburg', 'country': 'Germany', 'facility': 'Arena 1479', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'zip': '22559', 'city': 'Hamburg', 'country': 'Germany', 'facility': 'Arena 1422', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'zip': '30625', 'city': 'Hanover', 'country': 'Germany', 'facility': 'Arena 1470', 'geoPoint': {'lat': 52.37052, 'lon': 9.73322}}, {'zip': '24105', 'city': 'Kiel', 'country': 'Germany', 'facility': 'Arena 1446', 'geoPoint': {'lat': 54.32133, 'lon': 10.13489}}, {'zip': '04103', 'city': 'Leipzig', 'country': 'Germany', 'facility': 'Arena 1489', 'geoPoint': {'lat': 51.33962, 'lon': 12.37129}}, {'zip': '26123', 'city': 'Oldenburg', 'country': 'Germany', 'facility': 'Arena 1497', 'geoPoint': {'lat': 53.14039, 'lon': 8.21479}}, {'zip': '89073', 'city': 'Ulm', 'country': 'Germany', 'facility': 'Arena 1444', 'geoPoint': {'lat': 48.39841, 'lon': 9.99155}}, {'zip': '5600', 'city': 'Békéscsaba', 'country': 'Hungary', 'facility': 'Arena 1478', 'geoPoint': {'lat': 46.68333, 'lon': 21.1}}, {'zip': '1036', 'city': 'Budapest', 'country': 'Hungary', 'facility': 'Arena 1431', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'zip': '1062', 'city': 'Budapest', 'country': 'Hungary', 'facility': 'Arena 1471', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'zip': '1062', 'city': 'Budapest', 'country': 'Hungary', 'facility': 'Arena 1492', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'zip': '4025', 'city': 'Debrecen', 'country': 'Hungary', 'facility': 'Arena 1505', 'geoPoint': {'lat': 47.53167, 'lon': 21.62444}}, {'zip': '4032', 'city': 'Debrecen', 'country': 'Hungary', 'facility': 'Arena 1474', 'geoPoint': {'lat': 47.53167, 'lon': 21.62444}}, {'zip': '9700', 'city': 'Szombathely', 'country': 'Hungary', 'facility': 'Arena 1477', 'geoPoint': {'lat': 47.23088, 'lon': 16.62155}}, {'zip': '84101', 'city': 'Beersheba', 'country': 'Israel', 'facility': 'Arena 1705', 'geoPoint': {'lat': 31.25181, 'lon': 34.7913}}, {'zip': '31096', 'city': 'Haifa', 'country': 'Israel', 'facility': 'Arena 1702', 'geoPoint': {'lat': 32.81303, 'lon': 34.99928}}, {'zip': '58100', 'city': 'Holon', 'country': 'Israel', 'facility': 'Arena 1706', 'geoPoint': {'lat': 32.01034, 'lon': 34.77918}}, {'zip': '91031', 'city': 'Jerusalem', 'country': 'Israel', 'facility': 'Arena 1704', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}}, {'zip': '49100', 'city': 'Petah Tikva', 'country': 'Israel', 'facility': 'Arena 1703', 'geoPoint': {'lat': 32.08707, 'lon': 34.88747}}, {'zip': '1002', 'city': 'Riga', 'country': 'Latvia', 'facility': 'Arena 1462', 'geoPoint': {'lat': 56.946, 'lon': 24.10589}}, {'zip': '1006', 'city': 'Riga', 'country': 'Latvia', 'facility': 'Arena 1475', 'geoPoint': {'lat': 56.946, 'lon': 24.10589}}, {'zip': '8661', 'city': 'Vilnius', 'country': 'Lithuania', 'facility': 'Arena 1484', 'geoPoint': {'lat': 54.68916, 'lon': 25.2798}}, {'zip': '8011', 'city': 'Christchurch', 'country': 'New Zealand', 'facility': 'Arena 1601', 'geoPoint': {'lat': -43.53333, 'lon': 172.63333}}, {'zip': '85-681', 'city': 'Bydgoszcz', 'country': 'Poland', 'facility': 'Arena 1439', 'geoPoint': {'lat': 53.1235, 'lon': 18.00762}}, {'zip': '82-300', 'city': 'Elblag', 'country': 'Poland', 'facility': 'Arena 1486', 'geoPoint': {'lat': 54.1522, 'lon': 19.40884}}, {'zip': '25-364', 'city': 'Kielce', 'country': 'Poland', 'facility': 'Arena 1495', 'geoPoint': {'lat': 50.87033, 'lon': 20.62752}}, {'zip': '31-009', 'city': 'Krakow', 'country': 'Poland', 'facility': 'Arena 1451', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'zip': '90-302', 'city': 'Lodz', 'country': 'Poland', 'facility': 'Arena 1438', 'geoPoint': {'lat': 51.77058, 'lon': 19.47395}}, {'zip': '60-856', 'city': 'Poznan', 'country': 'Poland', 'facility': 'Arena 1458', 'geoPoint': {'lat': 52.40692, 'lon': 16.92993}}, {'zip': '35-068', 'city': 'Rzeszów', 'country': 'Poland', 'facility': 'Arena 1428', 'geoPoint': {'lat': 50.04132, 'lon': 21.99901}}, {'zip': '81-756', 'city': 'Sopot', 'country': 'Poland', 'facility': 'Arena 1456', 'geoPoint': {'lat': 54.4418, 'lon': 18.56003}}, {'zip': '54-144', 'city': 'Wroclaw', 'country': 'Poland', 'facility': 'Arena 1494', 'geoPoint': {'lat': 51.10286, 'lon': 17.03006}}, {'zip': '010719', 'city': 'Bucharest', 'country': 'Romania', 'facility': 'Arena 1491', 'geoPoint': {'lat': 44.43225, 'lon': 26.10626}}, {'zip': '020125', 'city': 'Bucharest', 'country': 'Romania', 'facility': 'Arena 1406', 'geoPoint': {'lat': 44.43225, 'lon': 26.10626}}, {'zip': '050098', 'city': 'Bucharest', 'country': 'Romania', 'facility': 'Arena 1441', 'geoPoint': {'lat': 44.43225, 'lon': 26.10626}}, {'zip': '700506', 'city': 'Iași', 'country': 'Romania', 'facility': 'Arena 1436', 'geoPoint': {'lat': 47.16667, 'lon': 27.6}}, {'zip': '410159', 'city': 'Oradea', 'country': 'Romania', 'facility': 'Arena 1420', 'geoPoint': {'lat': 47.0458, 'lon': 21.91833}}, {'zip': '300002', 'city': 'Timișoara', 'country': 'Romania', 'facility': 'Arena 1405', 'geoPoint': {'lat': 45.75372, 'lon': 21.22571}}, {'zip': '300736', 'city': 'Timișoara', 'country': 'Romania', 'facility': 'Arena 1493', 'geoPoint': {'lat': 45.75372, 'lon': 21.22571}}, {'zip': '660022', 'city': 'Krasnoyarsk', 'country': 'Russia', 'facility': 'Arena 1500', 'geoPoint': {'lat': 56.03742, 'lon': 92.93136}}, {'zip': '630091', 'city': 'Novosibirsk', 'country': 'Russia', 'facility': 'Arena 1504', 'geoPoint': {'lat': 55.02259, 'lon': 82.93175}}, {'zip': '344022', 'city': 'Rostov-on-Don', 'country': 'Russia', 'facility': 'Arena 1419', 'geoPoint': {'lat': 47.21997, 'lon': 39.70769}}, {'zip': '191015', 'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'Arena 1498', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '191186', 'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'Arena 1448', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '443063', 'city': 'Samara', 'country': 'Russia', 'facility': 'Arena 1465', 'geoPoint': {'lat': 53.20767, 'lon': 50.13553}}, {'zip': '26426', 'city': 'Wŏnju', 'state': 'Gangwon-do', 'country': 'South Korea', 'facility': 'Arena 1615', 'geoPoint': {'lat': 37.35139, 'lon': 127.94528}}, {'zip': '42415', 'city': 'Daegu', 'country': 'South Korea', 'facility': 'Arena 1614', 'geoPoint': {'lat': 35.87028, 'lon': 128.59111}}, {'zip': '21565', 'city': 'Incheon', 'country': 'South Korea', 'facility': 'Arena 1610', 'geoPoint': {'lat': 37.45646, 'lon': 126.70515}}, {'zip': '08022', 'city': 'Barcelona', 'country': 'Spain', 'facility': 'Arena 1403', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '08036', 'city': 'Barcelona', 'country': 'Spain', 'facility': 'Arena 1460', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '28046', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Arena 1481', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '36071', 'city': 'Pontevedra', 'country': 'Spain', 'facility': 'Arena 1430', 'geoPoint': {'lat': 42.431, 'lon': -8.64435}}, {'zip': '15706', 'city': 'Santiago de Compostela', 'country': 'Spain', 'facility': 'Arena 1432', 'geoPoint': {'lat': 42.88052, 'lon': -8.54569}}, {'zip': '41071', 'city': 'Seville', 'country': 'Spain', 'facility': 'Arena 1469', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'zip': '03110', 'city': 'Chernivtsi', 'country': 'Ukraine', 'facility': 'Arena 1424', 'geoPoint': {'lat': 48.29045, 'lon': 25.93241}}, {'zip': '76018', 'city': 'Ivano-Frankivsk', 'country': 'Ukraine', 'facility': 'Arena 1445', 'geoPoint': {'lat': 48.92312, 'lon': 24.71248}}, {'zip': '06100', 'city': 'Kharkiv', 'country': 'Ukraine', 'facility': 'Arena 1454', 'geoPoint': {'lat': 49.98177, 'lon': 36.25475}}, {'zip': '61039', 'city': 'Kharkiv', 'country': 'Ukraine', 'facility': 'Arena 1459', 'geoPoint': {'lat': 49.98177, 'lon': 36.25475}}, {'zip': '01030', 'city': 'Kiev', 'country': 'Ukraine', 'facility': 'Arena 1466', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'zip': '04201', 'city': 'Kiev', 'country': 'Ukraine', 'facility': 'Arena 1411', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'zip': '01030', 'city': 'Kyiv', 'country': 'Ukraine', 'facility': 'Arena 1408', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'zip': '02091', 'city': 'Kyiv', 'country': 'Ukraine', 'facility': 'Arena 1506', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'zip': '65025', 'city': 'Odesa', 'country': 'Ukraine', 'facility': 'Arena 1414', 'geoPoint': {'lat': 46.48572, 'lon': 30.74383}}, {'zip': '88018', 'city': 'Uzhhorod', 'country': 'Ukraine', 'facility': 'Arena 1433', 'geoPoint': {'lat': 48.6242, 'lon': 22.2947}}, {'zip': '21018', 'city': 'Vinnytsia', 'country': 'Ukraine', 'facility': 'Arena 1416', 'geoPoint': {'lat': 49.2322, 'lon': 28.46871}}, {'zip': '21029', 'city': 'Vinnytsia', 'country': 'Ukraine', 'facility': 'Arena 1501', 'geoPoint': {'lat': 49.2322, 'lon': 28.46871}}, {'zip': 'E1 1BB', 'city': 'London', 'country': 'United Kingdom', 'facility': 'Arena 1302', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'TQ2 7AA', 'city': 'Torquay', 'country': 'United Kingdom', 'facility': 'Arena 1304', 'geoPoint': {'lat': 50.46198, 'lon': -3.52522}}, {'zip': 'WV10 0QP', 'city': 'Wolverhampton', 'country': 'United Kingdom', 'facility': 'Arena 1303', 'geoPoint': {'lat': 52.58547, 'lon': -2.12296}}], 'overallOfficials': [{'name': 'Arena CT.gov Administrator', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Arena Pharmaceuticals'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Arena Pharmaceuticals', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}